Hepatitis D

10 trials 3 recruiting MedDRA PT
10 Registered trials
3 Recruiting
3 Unique sponsors
6 Unique IMPs
10 Commercial trials
Drug classes (ATC)
— ATC code not specified 7
J Anti-infectives (ATC J) 3
Mechanism of action (INN-stem analysis)
Unknown / small molecule 4 substances
Antiviral 1 substance
siRNA 1 substance
Phase III: 4 Phase II/III: 2 Phase II: 3 Phase I/II: 1

Filter these 10 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 10 trials

Phase III

4 trials
  • Bluejay Therapeutics Inc. Commercial
    BJT-778
    2024-517167-23-00 8 countries 2025 n=141 Orphan
    Recruiting
  • Bluejay Therapeutics Inc. Commercial
    BJT-778
    2025-522105-38-00 3 countries 2026 n=35 Orphan
    Ended
  • Vir Biotechnology Inc. Commercial
    ELEBSIRAN; TOBEVIBART
    2024-515919-22-00 3 countries 2025 n=27 Orphan
    Ended
  • Vir Biotechnology Inc. Commercial
    BULEVIRTIDE; ELEBSIRAN; TOBEVIBART
    2024-519282-22-00 6 countries 2025 n=136 Orphan
    Recruiting

Phase II/III

2 trials
  • Bluejay Therapeutics Inc. Commercial
    BJT-778
    2024-519063-18-00 1 country 2025 n=30 Orphan
    Ended
  • Bluejay Therapeutics Inc. Commercial
    BJT-778
    2025-522015-42-00 7 countries 2026 n=115 Orphan
    Recruiting

Phase II

3 trials
  • Ribocure Pharmaceuticals AB Commercial
    RBD1016; TENOFOVIR ALAFENAMIDE
    2023-509007-33-00 1 country 2024 n=15 Orphan
    Ended
  • Vir Biotechnology Inc. Commercial
    ELEBSIRAN; TOBEVIBART
    2024-512203-40-00 6 countries 2022 n=119
    Ended
  • Vir Biotechnology Inc. Commercial
    BULEVIRTIDE; ELEBSIRAN; TOBEVIBART
    2024-520062-54-00 8 countries 2025 n=42 Orphan
    Ended

Phase I/II

1 trial
  • Bluejay Therapeutics Inc. Commercial
    BJT-778
    2022-502724-46-00 3 countries n=16
    Expired
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Bluejay Therapeutics Inc. Commercial 5 Phase II/III, Phase III, Phase I/II 2
Vir Biotechnology Inc. Commercial 4 Phase II, Phase III 1
Ribocure Pharmaceuticals AB Commercial 1 Phase II 0
New trials by year
2022
1
2024
1
2025
5
2026
2
← All indication landscapes